Transbronchial cryobiopsies (TBCB) have recently been introduced as a promising and
safer alternative to surgical lung biopsy in the diagnostic approach to diffuse parenchymal …

Interstitial lung diseases are a group of diffuse parenchymal lung disorders associated with
substantial morbidity and mortality. Knowledge achieved in recent years has resulted in the …

The goal of this review is to summarise the clinical features, management, and prognosis of
acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF). AE-IPF has previously been …

Background Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the
European Medicines Agency and the US Food and Drug Administration for the treatment of …

Background: Pirfenidone is a novel antifibrotic drug for the treatment of mild-to-moderate
idiopathic pulmonary fibrosis (IPF). However, adverse events may offset treatment benefits …

Fibrosing lung disorders include a large number of diseases with diverse behaviour.
Patients can die because of the progression of their illness, remain stable or even improve …

Background Idiopathic pulmonary fibrosis acute exacerbation (IPF-AE) constitutes IPF's most
devastating event, representing the unexpected superimposition of diffuse alveolar damage …

Purpose There is no established standard regimen for non-small cell lung cancer (NSCLC)
patients with interstitial lung disease (ILD). For them, we performed a pilot study to evaluate …

Background Acute exacerbation of interstitial lung disease (AE-ILD) is the most serious
complication in lung cancer patients with pre-existing ILD receiving chemotherapy. The role …

Idiopathic pulmonary fibrosis (IPF) is a gradual lung disease with a survival of less than 5
years post-diagnosis for most patients. Poor molecular description of IPF has led to …